SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. on September 4, 2008. The registrant is a Colorado-based biotechnology company focused on developing diagnostic tests. Note: The request metadata referenced "Riot Platforms, Inc."; however, the provided filing text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes and Events
- Clinical Trial Progress: The company announced that patient enrollment for its FDA 510(k) clinical trial for AppyScore® is nearing the halfway point.
- Product Focus: AppyScore is described as the world's first appendicitis blood test.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a detailed discussion of risks and contingencies beyond the context of the clinical trial progress. The primary purpose is to disclose the status of the regulatory trial.
Key Facts for Investor Verification
- Verify the exact enrollment numbers and timeline for the AppyScore FDA 510(k) clinical trial.
- Confirm the regulatory status and requirements for the 510(k) clearance process for appendicitis blood tests.
- Review the attached press release (Exhibit 99.1) for specific details on the trial design and interim results.
- Clarify the discrepancy between the requested company name (Riot Platforms) and the actual filing registrant (AspenBio Pharma).